Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADA | P00813 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838477 | 0.89 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL29815502 | 0.85 | ADORA2A (0.79) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| Ammonia Solution, Strong SCHEMBL19974416 | 0.85 | ADORA2A (0.79) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19974575 | 0.85 | ADORA2A (0.43) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19979046 | 0.81 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL22683313 | 0.78 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL21511191 | 0.78 | ADORA3 (0.43) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL19974374 | 0.78 | ADORA3 (0.43) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL19987356 | 0.78 | ADORA3 (0.43) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL19974375 | 0.78 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | LCB PHARMA INC. (CA) | 2022-09-06 | — | — | US | disclosed |
| EP-3512860-B1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC (CA) | 2020-11-25 | — | — | EP | disclosed |
| EP-3512860-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB Pharma Inc. (CA) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | TNNT2, NT5C2, PNP | ADORA2A 57/4885ADORA3 68/4885ADORA1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.